64 related articles for article (PubMed ID: 23570435)
1. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
2. Benefits of introduction of Oncotype DX
Green N; Al-Allak A; Fowler C
Ann R Coll Surg Engl; 2019 Jan; 101(1):55-59. PubMed ID: 30322288
[TBL] [Abstract][Full Text] [Related]
3. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Yamauchi H; Nakagawa C; Yamashige S; Takei H; Yagata H; Yoshida A; Hayashi N; Hornberger J; Yu T; Chao C; Yoshizawa C; Nakamura S
BMC Health Serv Res; 2014 Sep; 14():372. PubMed ID: 25190451
[TBL] [Abstract][Full Text] [Related]
4. A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
Holt S; Verrill M; Pettit L; Rigg A; Hickish T; Archer C; Dent J; Dillon M; Nathan M; Barthelmes L; Rehman S; Sharaiha Y; Innis P; Sai-Giridhar P; Khawaja S
Br J Cancer; 2024 Apr; 130(7):1149-1156. PubMed ID: 38308000
[TBL] [Abstract][Full Text] [Related]
5. The Role of the 21-Gene Recurrence Score
Yordanova M; Hassan S
Curr Oncol; 2022 Mar; 29(3):2008-2020. PubMed ID: 35323363
[TBL] [Abstract][Full Text] [Related]
6. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):66-73. PubMed ID: 19125125
[TBL] [Abstract][Full Text] [Related]
7. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Zanotti L; Bottini A; Rossi C; Generali D; Cappelletti MR
Tumour Biol; 2014 Sep; 35(9):8461-70. PubMed ID: 25048969
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY; Dang W; Richman I; Mougalian SS; Evans SB; Gross CP
J Clin Oncol; 2018 Jun; 36(16):1619-1627. PubMed ID: 29659329
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the 21-gene recurrence score test in the United States in 2011.
Lynch JA; Berse B; Petkov V; Filipski K; Zhou Y; Khoury MJ; Hassett M; Freedman AN
Genet Med; 2016 Oct; 18(10):982-90. PubMed ID: 26890451
[TBL] [Abstract][Full Text] [Related]
12. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
[TBL] [Abstract][Full Text] [Related]
14. Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
Lamond NW; Skedgel C; Younis T
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):243-50. PubMed ID: 23570435
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
Lamond NW; Skedgel C; Rayson D; Lethbridge L; Younis T
Breast Cancer Res Treat; 2012 Jun; 133(3):1115-23. PubMed ID: 22361999
[TBL] [Abstract][Full Text] [Related]
16. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
18. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
